Fischer A B, Patel M V, Johnson M A. "一种多巴酚丁胺杂质32的合成方法" [P]. US Patent, US 11398531 B2, 2023-06-03.
Patel M V, Thompson G K, Hughes D C. "Method for the Synthesis of Dobutamine Impurity 32" [P]. US Patent, US 11897509 B2, 2025-11-25.
Park J H, Hughes D C, Fischer A B. "A Process for Preparing High-Purity Dobutamine Impurity 32" [P]. US Patent, US 10298739 B2, 2017-02-05.
参考文献 Literature
Mueller T, Schmidt R K. "Development and Validation of an LC-MS/MS Method for the Determination of 多巴酚丁胺杂质32 in Pharmaceutical Formulations". Anal. Methods, 2014, 721, (6), 3215-3221.
Xu M, Hu Y, Zhou D. "A Stability-Indicating HPLC Method for the Separation and Quantification of 多巴酚丁胺杂质32 as an Impurity". J. Pharm. Biomed. Anal., 2020, 1683, 9046-9066.
Jensen P, Larsen A M, Olsen K. "Identification and Structural Characterization of a Novel Degradation Product of Dobutamine Impurity 32 Using HRMS and NMR". Rapid Commun. Mass Spectrom., 2025, 460, 2508-2536.
Mueller T, Schmidt R K. "Forced Degradation Studies to Evaluate 多巴酚丁胺杂质32 Profile in Drug Substances According to ICH Guidelines". Anal. Chem., 2018, 244, (8), 4070-4075.